You are correct. $35 is better than $8.6.
However $350 is better than $35.
And I do expect a partnership leading up to a buyout.
A partnership alone could bring the share price closer to $100.
Approvals in Australia, UK, Europe and Canada...and the US could triple that.
The safest and most effective prevention and /or treatment for treatment for ALzheimers, PDD, Retts, Fragile X, Autism etc. could easily produce revenues over $20 billion a year. Final share price? 4 digits is entirely possible IMO!